Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cryo Cell International (CCEL) Equity Average (2016 - 2025)

Cryo Cell International (CCEL) has disclosed Equity Average for 15 consecutive years, with -$16.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Equity Average fell 46.82% to -$16.7 million in Q4 2025 year-over-year; TTM through Nov 2025 was -$16.7 million, a 46.82% decrease, with the full-year FY2025 number at -$15.9 million, down 31.24% from a year prior.
  • Equity Average was -$16.7 million for Q4 2025 at Cryo Cell International, down from -$15.2 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $4.5 million in Q4 2021 to a low of -$16.7 million in Q4 2025.
  • A 5-year average of -$4.8 million and a median of -$2.1 million in 2021 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: surged 293.47% in 2022, then plummeted 2221.24% in 2024.
  • Cryo Cell International's Equity Average stood at $4.5 million in 2021, then crashed by 143.52% to -$2.0 million in 2022, then tumbled by 182.55% to -$5.5 million in 2023, then plummeted by 106.16% to -$11.4 million in 2024, then crashed by 46.82% to -$16.7 million in 2025.
  • Per Business Quant, the three most recent readings for CCEL's Equity Average are -$16.7 million (Q4 2025), -$15.2 million (Q3 2025), and -$15.1 million (Q2 2025).